Possible serious side effects of RYBREVANT® include:
-related reactions are common with RYBREVANT® and can be severe or serious. Tell your doctor right away if you experience infusion-related reactions (shortness of breath, fever, chills, nausea, flushing, chest discomfort, lightheadedness, vomiting), with most occurring during the first infusion. Your treatment team may adjust or pause your infusion dosing and timing to help manage any reactions that may occur.
You may experience severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Tell your doctor right away if you have any skin reactions. They may treat you with medicine(s) or send you to see a skin specialist (dermatologist). It may be helpful to proactively take steps to minimize any discomfort. Please read the proactive steps you can take here.
You may experience lung problems that may lead to death. Signs and symptoms of lung problems may be similar to those of lung cancer. Some of the common signs to watch out for are shortness of breath, cough, or fever. Tell your doctor right away if you have any new or worsening lung problems.
You may experience eye problems, which may include eye pain, inflammation of eyelids, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, or sensitivity to light. Your doctor may refer you to an eye specialist (ophthalmologist). You should not use contact lenses until your eye symptoms are checked by a healthcare provider.
RYBREVANT® can harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. If you are able to become pregnant you should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT®. Tell your healthcare provider right away if you become pregnant or think you might be pregnant.
If your partner is able to become pregnant, you should use effective birth control during treatment.
Your care team can help prevent or manage side effects to help you stay on treatment.
A general guide to RYBREVANT® for the second treatment of NSCLC with exon 20 insertion mutations.
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
EGFR = epidermal growth factor receptor, NSCLC = non–small cell lung cancer.